Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+80 21-DAY vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol undergoes first-pass metabolism in the intestinal wall and liver via CYP3A4, with conjugation and enterohepatic recirculation. Norethindrone is metabolized in the liver primarily via reduction and conjugation, with CYP3A4 involvement. Both are excreted in urine and feces.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal (40-60% as metabolites), fecal (20-30%)
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 61% bound to albumin and SHBG; Mestranol/ethinyl estradiol: 98% bound to albumin
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 3.6 L/kg; Mestranol/ethinyl estradiol: 1.5-4.0 L/kg
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: norethindrone ~64%; mestranol ~40-60% (prodrug, converted to ethinyl estradiol)
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No specific dose adjustment required for renal impairment. Use with caution in patients with renal dysfunction.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks and monitor liver function closely.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. For adolescents post-menarche, same adult dosing: one tablet orally once daily for 21 days, then 7-day pill-free interval.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use after menopause. No specific dose adjustments in elderly women of reproductive age; standard adult dosing applies.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age (especially >35 years) and heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic events (venous thromboembolism, stroke, MI),Cigarette smoking,Hypertension,Gallbladder disease,Hepatic neoplasia,Carbohydrate/lipid effects,Headache/migraine,Bleeding irregularities,Use in pregnancy,Diabetes,Depression,Hereditary angioedema,Chloasma,Hepatic impairment,Renal impairment,Breast cancer risk
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Active liver disease with abnormal liver function,Hypersensitivity to any component,Diabetes with vascular involvement,Uncontrolled hypertension,Major surgery with prolonged immobilization,Migraine with focal aura or over age 35 with any migraine
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but effect is minimal. Maintain consistent intake to avoid gastrointestinal upset.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: No conclusive evidence of major malformations from combined hormonal contraceptives; however, data are limited. Second/third trimester: Use is contraindicated due to possible adverse effects on fetal development, including potential masculinization of female genitalia (androgenic progestin) and other hormonal effects, though the risk is low with norethindrone. Postnatal: No specific long-term effects documented.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of norethindrone and ethinyl estradiol excreted in breast milk; M/P ratio not established. Use is not recommended during breastfeeding as estrogen may reduce milk production and quality; progestin-only contraception preferred.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dose adjustments are applicable; use is contraindicated during pregnancy. If unintended pregnancy occurs, immediate discontinuation is advised.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
NORINYL 1+80 21-DAY is a high-estrogen-dose combination oral contraceptive (1 mg norethindrone, 80 mcg mestranol). Use with caution in patients with cardiovascular risk factors; contraindicated in women over 35 who smoke. Mestranol is a prodrug that requires hepatic conversion to ethinyl estradiol; lower potency compared to ethinyl estradiol on a mcg basis. Monitor for thromboembolic events, especially in the first year of use. Consider alternative formulations if breakthrough bleeding occurs.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time each day for 21 days, then no tablets for 7 days.,If you miss a pill, follow the package instructions; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Seek immediate medical attention for sudden chest pain, shortness of breath, leg pain or swelling, severe headache, or vision changes.,Inform your healthcare provider if you smoke or have a history of blood clots, migraines, or hypertension.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+80 21-DAY vs ALYACEN 1/35, answered by our medical review team.
NORINYL 1+80 21-DAY is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+80 21-DAY and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+80 21-DAY is: One tablet orally once daily for 21 days, followed by 7 days of no active treatment.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+80 21-DAY and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+80 21-DAY is classified as Category C. First trimester: No conclusive evidence of major malformations from combined hormonal contraceptives; however, data are limited. Second/third trimester: Use is contraindicated due . ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.